VSIG4 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q9Y279 |
---|---|
Clone Names | 110901252 |
Gene ID | 11326 |
---|---|
Other Names | V-set and immunoglobulin domain-containing protein 4, Protein Z39Ig, VSIG4, CRIg, Z39IG |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | VSIG4 |
---|---|
Synonyms | CRIg, Z39IG |
Function | Phagocytic receptor, strong negative regulator of T-cell proliferation and IL2 production. Potent inhibitor of the alternative complement pathway convertases. |
Cellular Location | Membrane; Single-pass type I membrane protein |
Tissue Location | Abundantly expressed in several fetal tissues. In adult tissues, highest expression in lung and placenta. Expressed in resting macrophages. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a v-set and immunoglobulin-domaincontaining protein that is structurally related to the B7 family ofimmune regulatory proteins. The encoded protein may be a negativeregulator of T-cell responses. This protein is also a receptor forthe complement component 3 fragments C3b and iC3b. Alternatesplicing results in multiple transcript variants. [provided byRefSeq].
References
Guo, S., et al. Clin. Immunol. 136(2):282-291(2010)Van Loo, P., et al. Haematologica 95(3):440-448(2010)Xu, S., et al. Immunol. Lett. 128(1):46-50(2010)He, J.Q., et al. Mol. Immunol. 45(16):4041-4047(2008)Vogt, L., et al. J. Clin. Invest. 116(10):2817-2826(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.